Chemours Company (the) · NYSE:CC

Chemours Company (the) — Q4 2023 Earnings Presentation

16 slides from Chemours Company (the)'s earnings presentation, Feb 29, 2024

  1. Slide 1: Full Year 2023 Earnings Presentation

    Full Year 2023 Earnings Presentation March 28, 2024

  2. Slide 2: Safe Harbor Statement and Other Matters

    Safe Harbor Statement and Other Matters This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current exp

  3. Slide 3: Full Year 2023 Financial Summary

    Full Year 2023 Financial Summary ($ in millions unless otherwise noted; excludes per share amounts) ∆ Year-Over-Year FY’23 FY’22 Yr/Yr  Net Sales: Decreased by (11)% to $6.0 billion, primarily due to volume declines in TT and the Net Sales $6,027 $6,794 $(767) Advanced Materials portfolio in APM Pr

  4. Slide 4: Fourth Quarter 2023 Financial Summary

    Fourth Quarter 2023 Financial Summary ($ in millions unless otherwise noted; excludes per share amounts) ∆ Fourth Quarter vs Prior-Year Quarter 4Q23 4Q22 Yr/Yr  Net Sales: Increased by 2% to $1.4 billion, fueled by increased volumes in TT and TSS Net Sales $1,361 $1,338 $23  Earnings Per Share (EP

  5. Slide 5: Adjusted EBITDA Bridge: 2023 versus 2022

    AdjustedEBITDA Adjusted EBITDA Bridge: Bridge: 2023 versus 4Q22versus 4Q21 2022 ($ in millions unless otherwise noted) ($53) $124 Year-Over-Year ($365) • Price Increases: Primarily driven by higher pricing in TSS and APM segments, partially offset ($14) by price declines in market-exposed channels (

  6. Slide 6: Adjusted EBITDA Bridge: 4Q23 versus 4Q22

    AdjustedEBITDA Adjusted EBITDA Bridge: Bridge: 4Q23 versus 4Q22versus 4Q21 4Q22 ($ in millions unless otherwise noted) ($11) ($3) $78 Fourth Quarter vs Prior-Year Quarter • Price Declines: Primarily driven by lower pricing in market-exposed channels within the TT segment and higher pricing in TSS an

  7. Slide 7: Liquidity Position as of December 31, 2023

    Liquidity Position as of December 31, 2023 Liquidity Position Adjusted EBITDA Bridge: 4Q22 versus 4Q21 ($ in millions unless otherwise noted) Gross debt $4.1B Q4’23 Cash Position: Net Debt 9 $2.9B • Unrestricted Cash: $1.2 billion TTM Net Leverage 10 2.8x • Restricted Cash: $0.6 billion • Total Cash

  8. Slide 8: Segment Performance

    Segment Performance

  9. Slide 9: Titanium Technologies (TT) Business Summary

    Titanium Technologies (TT) Business Summary ($ in millions) Full Year and Fourth Quarter Highlights Net Sales  Full Year Performance: Driven by continuation of a cyclical downturn Total Price Volume Currency Total Price Volume Currency across all regions. Adjusted EBITDA and Margin declined due to

  10. Slide 10: Thermal & Specialized Solutions (TSS) Business Summary

    Thermal & Specialized Solutions (TSS) Business Summary ($ in millions) Full Year and Fourth Quarter Highlights Net Sales  Full Year Performance: Net Sales increased due to pricing Total Price Volume Currency Total Price Volume Currency portfolio-wide (ex. auto), value-based FP&O* pricing, and portf

  11. Slide 11: Advanced Performance Materials (APM) Business Summary

    Advanced Performance Materials (APM) Business Summary ($ in millions) Full Year and Fourth Quarter Highlights Net Sales  Full Year Performance: Driven by soft demand in economically sensitive Total Price Volume Currency Total Price Volume Currency end markets in the Advanced Materials portfolio, pa

  12. Slide 12: Appendix

    Appendix

  13. Slide 13: Segment Net Sales and Adjusted EBITDA (Unaudited)

    Segment Net Sales and Adjusted EBITDA (Unaudited) ($ in millions) Three Months Ended Three Months Ended Year Ended December 31, September 30, December 31, 2023 2022 2023 2023 2022 SEGMENT NET SALES Titanium Technologies $ 651 $ 606 $ 690 $ 2,680 $ 3,380 Thermal & Specialized Solutions 374 320 436 1,

  14. Slide 14: GAAP Net Income to Adjusted Net Income, Adjusted EBITDA Reconciliation (Page 1/2)

    GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EBITDA Margin Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 1/2) ($ in millions except per share amounts) Three Months Ended Three Months Ended Year Ended D

  15. Slide 15: GAAP Net Income to Adjusted EBITDA and Net Leverage Reconciliation (Page 2/2)

    GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EBITDA Margin Reconciliation (Unaudited) GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio (Page 2/2) ($ in millions except per share amounts) Three Months Ended Three Months Ended Year Ended D

  16. Slide 16: Thank you!

    Thank you!

Chemours Company (The) — Q4 2023 Earnings Presentation on 6ix